Trasylol Limited to Investigational Use
Bayer’s anti-bleeding drug Trasyslol will now only be available for investigational use, according to a statement released by the U.S. Food and Drug Administration.
Although Bayer has agreed to remove remaining stocks of Trasylol from the U.S. market, patients who are at a higher risk for blood loss during heart bypass surgery and who have no acceptable alternative treatment may be given Trasylol. However, a doctor must first verify that the “benefits of the drug clearly outweigh the risks for their patients.”
The news came after the BART study was published in the New England Journal of Medicine. The long-awaited study concluded that heart surgery patients given Trasylol had a 53 percent greater chance of dying than patients given cheaper competing drugs.
Since 2006, three studies have linked Trasylol to an increased risk for kidney damage, stroke and death.
Our firm currently represents several Trasylol victims and their families in lawsuits against Bayer. If you or a loved one suffered complications after taking Trasylol contact Carey & Danis. We can help. Carey & Danis is a national law firm that represents individuals injured by America's largest corporations.
For more information, fill out our online contact form or call Carey & Danis toll-free at 800-721-2519.
